Zelnorm Alternatives Compared
Zelnorm (tegaserod) | Linzess (linaclotide) | Trulance (plecanatide) |
|
---|
Zelnorm (tegaserod) | Linzess (linaclotide) | Trulance (plecanatide) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Irritable Bowel Syndrome with Constipation. Zelnorm may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation, Functional Constipation, Irritable Bowel Syndrome. Linzess may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation. Trulance may also be used for purposes not listed in this medication guide. |
Related suggestions Irritable Bowel Syndrome with Constipation
|
|||||||||||||||
More about Zelnorm | More about Linzess (linaclotide) | More about Trulance (plecanatide) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Zelnorm has an average rating of 8.8 out of 10 from a total of 42 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 11% reported a negative effect. |
Linzess has an average rating of 6.7 out of 10 from a total of 885 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 26% reported a negative effect. |
Trulance has an average rating of 6.0 out of 10 from a total of 276 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Linzess prices |
View all Trulance prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
16 hours |
N/A |
N/A |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 2 drugs are known to interact with Zelnorm:
|
A total of 59 drugs are known to interact with Linzess:
|
A total of 1 drugs are known to interact with Trulance:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
July 24, 2002 |
August 30, 2012 |
January 19, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.